Changing paradigms in thrombolysis in acute myocardial infarction

International Journal of Cardiology

Volumn 59, Issue 3, 1997, Pages 227-242

  Gotsman, Mervyn S ^a   Rozenman, Yoseph ^a   Admon, Dan ^a   Mosseri, Morris ^a   Lotan, Chaim ^a   Zahger, Doron ^a   Weiss, A Teddy ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Acute myocardial infarction; Coronary pathology; Reperfusion; Thrombolysis; Thrombotic occlusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATOBAN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; NATURAL PRODUCT; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE;

ACUTE HEART INFARCTION; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; ELECTROCARDIOGRAM; EMERGENCY TREATMENT; FIBRINOLYTIC THERAPY; GENERAL PRACTITIONER; HEART ARRHYTHMIA; HEART MUSCLE REPERFUSION; HUMAN; INTENSIVE CARE; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRIORITY JOURNAL; REPERFUSION INJURY; RESTENOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0030898158     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)02957-4     Document Type: Article

References (101)

1. Gotsman MS, Schrire V. Recent myocardial infarction in a teaching hospital - results without intensive care. S Afr Med J 1967;41:1166-1169.
2. Gotsman MS, Schrire V. Acute myocardial infarction: results of intensive coronary care. S Afr Med J 1968;42:1223-1230.
3. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-677.
4. Rouleau JL, Talajic M, Sussex B, Potvin L, Warnica With, Davies RE, Gardner M, Stewart D, Plante S, Dupuis R, Lauzon C, Ferguson J, Mikes E, Balnozan V, Savard P. Myocardial infarction patients in the 1990s - Their risk factors, stratification and survival in Canada: the Canadian assessment of myocardial infarction (CAMI) Study. J Am Coll Cardiol 1996;27:1119-1127.
5. Every NR, Parsons LS, Mark Hlatky BS, Martin JS, Weaver WD, for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335:1253-1317.
6. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
7. Stary HC. Evolution of atherosclerotic plaques in the coronary arteries of young adults. Arteriosclerosis 1983;3:471a.
8. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. A Definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 1995;92:1355-1374.
9. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic and Molecular Bases of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D, Seventh Edition, McGraw-Hill, Inc. Health Professions Division, 1995.
10. Steinberg D. Antioxidants and atherosclerosis: a current perspective. Circulation 1991;86:1420-1425.
11. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990;82:II47-II59.
12. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363-373.
13. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991;68:28B-35B.
14. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126.
15. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-1791.
16. Shepherd J, Cobbe SM, Ford I et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with provastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301.
17. Gotsman MS, Rosenheck S, Nassar H, Weiber S, Sapoznikov D, Mosseri M4 Weiss AT, Lotan C, Rozenman Y. Angiographic findings in the coronary arteries after thrombolysis in acute myocardial infarction. Am J Cardiol 1992;70:715-723.
18. Rozenman Y, Rosenheck S, Nassar H, Weiber S, Sapoznikov D, Lotan C, Mosseri M, Weiss AT, Gotsman MS. Acute myocardial infarction - the angiographie picture: new insights into the pathogenesis of myocardial infarction. Int J Cardiol 1995;49:S11-S16.
19. Forrester JS, Litvack F, Grundfest W, Hickey A. A perspective of coronary disease seen through the arteries of living man. Circulation 1987;75:505-513.
20. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The Dissociation between clinical and angiographie findings in ischemic heart disease. Circulation 1995;92:2333-2342.
21. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbard EB, Palacios I, Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986;73:347-351.
22. Reimer KA, Lowe JE, Rassmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death: myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation, 1977;56:786-794.
23. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol 1991;68:1D-6D.
24. Rozenman Y, Gotsman MS. The earliest diagnosis of acute myocardial infarction. In: Annu Rev Med: Selected Topics in the Clinical Sciences 1994;44:31-44.
25. Rozenman Y, Gotsman MS, Weiss AT, Lotan C, Mosseri M, Sapoznikov D, Weiber S, Hasin Y, Gilon D. Early intravenous thrombolysis in acute myocardial infarction: The Jerusalem experience. Int J Cardiol 1995;49:S21-S28.
26. Fine DG, Weiss AT, Sapoznikov D, Welber S, Appelbaum D, Lotan C, Hasin Y, Ben-David Y, Koren G, Gotsman MS. Importance of early initiation of intravenous streptokinase therapy for acute myocardial infarction. Am J Cardiol 1986;58:411-417.
27. Fine DG, Vinker S, Weiss AT, Welber S, Sapoznikov D, Lotan C, Mosseri M, Rosenheck S, Hasin Y, Gotsman MS. Influence of vessel involvement and early streptokinase therapy on regional and global left ventricular function in acute myocardial infarction. Herz 1987;12:398-404.
28. GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
29. Ottesen MM, Kober L, Jorgensen S, Torp-Pedersen C, on behalf of the TRACE Study Group. Determinants of delay between symptoms and hospital admission in 5978 patients with acute myocardial infarction. Eur Heart J 1996;17:429-437.
30. Martin GV, Kennedy JW. Choice of thrombolytic agent. In: Julian D, Braunwald E, editors. Management of Acute Myocardial Infarction. London: WB Saunders, 1993:71-105.
31. Simoons ML, Arnold AE. Tailored thrombolytic therapy. Circulation 1993;88:2556-2564.
32. Gotsman MS, Weiss AT. Immediate reperfusion in acute myocardial infarction. Biblthca Cardiol 1986;40:30-51.
33. Gotsman MS, Weiss AT, Mosseri M, Pollack A, Sapoznikov D, Hasin Y Prehospital and very early hospital management of acute myocardial infarction by high-dose rapid influsion of streptokinase. In: Sleight P, editor. Streptokinase for Acute Myocardial Infarction: Results and Implications of the Major Clinical Studies. MCS Consultants, Kent England, 1989:25-38.
34. Rozenman Y, Gotsman MS, Weiss AT, Lotan C, Mosseri M, Sapoznikov D, Welber S, Nassar H, Hasin Y, Gilon D. Very early thrombolysis in acute myocardial infarction - a light at the end of the tunnel. Isr J Med Sci 1994;30:99-107.
35. More R, Moore K, Quinn E, Avila CP, Davidson C, Vincent R, Chamberlain D. Delay times in the administration of thrombolytic therapy: the Brighton experience. Int J Cardiol 1995;49:S39-S46.
36. Coccolini S, Berti G, Bosi S, Pretolani M, Tumiotto G. Prehospital thrombolysis in rural emergency room and subsequent transport to a coronary care unit: Ravenna myocardial infarction (RaMI) trial. Int J Cardiol 1995;49:S47-S58.
37. Julian DG. Time as a factor in thrombolytic therapy. Int J Cardiol 1995;49:S17-S19.
38. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn AJ, Weaver WD. Treatment of myocardial infarction in the United States (1990-1993): Observations from the National Registry of myocardial infarction. Circulation 1994;90:2103-2114.
39. Kereiakes DJ, Weaver WD, Anderson JL et al. Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Am Heart J 1990;120:773-780.
40. Ho MT, Eisenberg MS, Litwin PE, Schaeffert SM, Damon SK. Delay between onset of chest pain and seeking medical care: the effect of public education. Ann Emerg Med 1989;18:727-731.
41. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993;320:383-389.
42. Boissel JP. The European Myocardial Infarction Project: an assessment of prehospital thrombolysis. Int J Cardiol 1995;49:S29-S37.
43. GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian Region Early Anistreplase Trial. Br Med J 1992;305:548-553.
44. Rawles J, on Behalf of the GREAT Group: halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994;23:1-5.
45. Koren G, Weiss AT, Hasin Y et al. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med 1985;313:1384-1389.
46. Appelbaum D, Weiss AT, Koren G, Hasin Y, Gotsman MS. Feasibility of prehospital fibrinolytic therapy of acute myocrdial infarction by emergency medical services. J Am Emerg Med 1986;4:207-210.
47. Weiss At, Fine DG, Applebaum D et al. Prehospital coronary thrombolysis: a new strategy in acute myocardial infarction. Chest 1987;92:124-128.
48. Grijseels EWM, Deckers JW, Hoes AW, Hartman AM, van der Does E, van Loenen E, Simoons ML. Prehospital triage of patients with suspected myocardial infarction: evaluation of previously developed algorithms and new proposals. Eur Heart J 1995;16:325-332.
49. Grijseels EWM, Bouten MJM, Lenderink T, Deckers JW, Hoes AW, Hartman JAM, van der Does E, Simoons ML. Prehospital thrombolytic therapy with either alteplase or streptokinase: practical applications, complications and long-term results in 529 patients. Eur Heart J 1995;16:1833-1838.
50. National Heart, Lung, and Blood Institute. Patient/bystander recognition and action: rapid identification and treatment of acute myocardial infarction. National Heart Attack Alert Program (NHAAP). Bethesda, Md: National Institutes of Health: 1993;NIH Publication No. 93-3303.
51. Newby LK, Rutsch WR, Califf RM, Simoons ML, Aylward PE, Armstrong PW, Woodlief LH, Lee KL, Topol EJ, van de Werf F, for the GUSTO-I Investigators: time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996;27:1646-1655.
52. Weaver WD, Eisenberg MS, Martin JS et al.: Myocardial infarction triage and intervention project - Phase I. Patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990;15:925-931.
53. The GUSTO Angiographie Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
54. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge Home thrombolysis, Francis CK, Hulls D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in myocardial infarction (TIMI) Trial, Phase I. a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987;76:142-154.
55. Harrington RA, Califf RM. The TAMI Trials. In: Becker RC, editor. The Modern Era of Coronary Thrombolysis. Kluwer Academic Publishers, Dordrecht, 1994; 91-106.
56. Weaver WD. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction. Eur Heart J 1996;17:14-20.
57. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993;87:1850-1853.
58. Ferguson JJ. Meeting Highlights, American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation 1996;94:1-5.
59. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.
60. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators N Engl J Med 1990;323:1433-1437.
61. Antman EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994;90:1624-1630.
62. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90:1522-1536.
63. Andersen JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL, for the TEAM-3 investigators. TIMI perfusion Grade 3 but not Grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic and electrocardiographic evidence from the TEAM-3 study. Circulation 1993;87:1829-1839.
64. Anderson JL, Karagounis LA, Califf RM. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996;78:1-8.
65. Serruys PW, Arnold AER, Brower RW et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986;73:347-351.
66. Welber S, Gotsman MS, Sapoznikov D, Rozenman Y, Lotan C, Koren G, Ben-David Y, Hasin Y, Weiss AT. Left ventricular function after prompt thrombolysis in acute myocardial infarction. In: Sideman S, Beyar R, editors. Simulation and Control of the Cardiac System, Volume II. Chapter 15:43-60, 1985, CRC Press, Inc., Boca Raton, Florida.
67. Grines CL, Browne KF, Marco J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
68. Zijlstra F, deBoer MJ, Hoorntje JCA, Reiffers S, Reiber HC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
69. Gibbons RJ, Holmes DR, Reeder GS et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-691.
70. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618-627.
71. The EPIC Investigators. Prevention of ischemic complications in high-risk angioplasty by a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein Iib/IIIa receptor. N Engl J Med 1994;330:956-961.
72. Simoons ML. Refractory unstable angina: reduction of events by C-7E3: the CAPTURE Study. Presented at the American College of Cardiology Annual Scientific Session; March 1996; Orlando, Fla.
73. Tcheng JE. Glycoprotein Iib/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into perspective. Am J Cardiol 1996;78:35-40.
74. de Bono DP, Simoons ML, Tijssen J, Arnold AE, Betriu A, Burgersdijk C Bescos LL, Mueller E, Pfistere M, Van de Werf F, Zijlstra F, Verstraete M, for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.
75. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis D, Hiratzka LF, Rapaport E, Riegel BJ, Russel RO, Smitt III EE, Weaver WD and the Task Force Members. ACC/AHA Guidelines for the Management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-1428.
76. Zabel KM, Granger CB, Becker Right coronary, Woodlief LH, Chesebro JH, Califf RM. Bedside aPTT monitoring is associated with less bleeding among GUSTO patients receiving i.v. heparin following thrombolytic administration. J Am Coll Cardiol (In press).
77. Fibrinolytic Therapy Trialist's (FTT) Collaborative Group: indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
78. Zahger D, Yano J, Chaux A, Fishbein MC, Ganz W. Absence of lethal reperfusion injury after three hours of reperfusion. A study in a single canine heart model of ischemia-reperfusion. Circulation 1995;91:2989-2994.
79. LATE study group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 h after onset of acute myocardial infarction. Lancet 1993;342:759-766.
80. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America sel Sur) Collaborative Group. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993;342:767-772.
81. Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Podrid PJ. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. J Am Coll Cardiol 1993;22:1773-1779.
82. White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:61-67.
83. Marber MS, Brown DL, Kloner RA. The open artery hypothesis: to open, or not to open, that is the question. Eur Heart J 1996;17:505-509.
84. Uebis R. How to estimate reocclusion risk?: In: Effert S, von Essen R, Hugenholtz PG, Uebis R, Verstraete M, editors. 'Facts and Hopes in Thrombolysis in Acute Myocardial Infarction', (International Symposium Aachen). Steinkopff Verlag Darmstadt, Springer-Verlag, New York, 1985.
85. Koren G, Luria MH, Weiss AT, Kriwsky M, Mosseri M, Lotan C, Applebaum D, Weiber S, Sapoznikov D, Ben-David Y, Hasin Y, Gotsman MS. Early treatment of acute myocardial infarction with intravenous streptokinase. Arch Intern Med 1987;147:237-240.
86. Meijer A, Verheugt FWA, van Eenige MJ, Werter CJPJ. Left ventricular function at 3 months after successful thrombolysis: impact of reocclusion without reinfarction on ejection fraction, regional function, and remodelling. Circulation 1994;90:1706-1714.
87. Krukoff MW, Croll MA, Pope JE et al. Continuously updated ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographie observations. Am J Cardiol 1993;72:145-151.
88. Kruckoff MW, Croll MA, Pope JE et al. Continuous 12-lead ST segment recovery analysis: a non-invasive method for real time detection of failed myocardial reperfusion. Circulation 1993;88:437-446.
89. von Essen R, Schmidt W, Uebis R, Edelmann B, Effert S, Silny J, Rau G. Myocardial infarction and thrombolysis. Electrocardiographic short term and long term results using precordial mapping. Br Heart J 1985;54:6-10.
90. Hindman NB, Schocken DD, Widmann M, Anderson WD, White RD, Leggett S, Ideker RE, Hinohara T, Selvester RH, Wagner GS. Evaluation of a QRS scoring system for estimating myocardial infarct size. V. Specificity and method of application of the complete system. Am J Cardiol 1985;55:1485.
91. Sabia P, Abbott RD, Afrookteh A, Keller MW, Touchstone DA, Kaul S. Importance of two-dimensional echocardiographic assessment of left ventricular systolic function in patients presenting to the emergency room with cardiac-related symptoms. Circulation 1991;84:1615-1624.
92. Chareonthaitawee P, Christian TF, Hirose K, Gibbons RJ, Rumberger JA. Relation of initial infarct size to extent of left ventricular remodelling in the year after acute myocardial infarction. J Am Coll Cardiol 1995;25:567-573.
93. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 199;18:397-402.
94. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
95. Behar S, Abinader E, Caspi A, David D, Flich M, Friedman Y, Hod H, Kaplinsky E, Kishon Y, Kristal N, Laniado S, Markiewicz V, Marmor A, Palant A, Pelled B, Reisin L, Rosenfeld T, Roguin N, Sherf L, Rabinowitz B, Schlesinger Z, Sclarovsky S, Zahavi I, Zion M, Goldouurt U. Frequency of use of thrombolytic therapy in acute myocardial infarction in Israel. Am J Cardiol 1991;68:1291-1294.
96. Lincoff AM, Topol EJ. Illusion of reperfusion. Circulation 1993;1361-1374.
97. Zahger D, Gotsman MS. Effect of reperfusion therapy for acute myocardial infarction on ventricular function and heart failure. Heart Fail Rev 1996;1:97-104.
98. Zahger D, Gotsman MS. Thrombolysis in the era of the randomized trials. Curr Opin Cardiol 1995;10:372-380.
99. Simoons ML, Vos J, Tijssen JGP, Vermeer F, Verheugt FWA, Krauss XH, Cats VM. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5-year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989;14:1609-1615.
100. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
101. Sacks FM, Pfeffer MA, Braunwald E et al for the CARE Investigators. Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: preliminary results of the Cholesterol and Recurrent Events (CARE) trial. Presented at the American College of Cardiology Annual Scientific Session, March 1996; Orlando, Fla.